Keyphrases
Rhabdomyosarcoma
98%
Children's Oncology Group
74%
Chemotherapy
29%
Ifosfamide
26%
Intermediate Risk
26%
Cyclophosphamide
23%
Event-free Survival
23%
Tumor
22%
Osteosarcoma
22%
Etoposide
19%
Ewing Sarcoma
18%
Soft Tissue Sarcoma
17%
Overall Survival
14%
Local Control
14%
Radiation Therapy
13%
Radiotherapy
12%
Lung
12%
Pediatric Patients
11%
Confidence Interval
11%
Failure-free Survival
11%
Group Studies
10%
Dactinomycin
10%
Bladder
10%
Working Diagnosis
10%
Neutropenia
10%
Granulocyte Colony-stimulating Factor (G-CSF)
10%
Irradiation
9%
Liposomal Amphotericin B
9%
Histology
9%
Prostate
9%
Metastatic Disease
9%
Acute Myeloid Leukemia
9%
Doxorubicin
8%
Pediatric
8%
Idarubicin
7%
Pharmacokinetic Study
7%
Survival Rate
7%
Chemotherapy Regimen
7%
High Dose
7%
Local Failure
7%
Metastatic Rhabdomyosarcoma
7%
Mayo Clinic
7%
Low Toxicity
7%
Phase I Trial
7%
Doxorubicin-cyclophosphamide
7%
Clinical Outcomes
7%
Risk Factors
7%
Newly Diagnosed
7%
Lung Metastasis
7%
Antifungal Therapy
6%
Medicine and Dentistry
Rhabdomyosarcoma
100%
Oncology
72%
Neoplasm
46%
Osteosarcoma
32%
Radiation Therapy
26%
Soft Tissue Sarcoma
24%
Vincristine
21%
Ewing Sarcoma
21%
Event Free Survival
20%
Cyclophosphamide
18%
Diseases
18%
Ifosfamide
17%
Metastatic Carcinoma
16%
Overall Survival
15%
Lung Metastasis
13%
Etoposide
13%
Recurrent Disease
13%
Doxorubicin
12%
Connective Tissue Cancer
12%
Pediatrics
11%
Lung
10%
Dactinomycin
10%
Survival Rate
10%
Bladder
9%
Drug Megadose
8%
Failure Free Survival
8%
Primary Tumor
8%
Biopsy Technique
7%
Neutropenia
7%
Pediatrics Patient
7%
Lymph Node
6%
Prognostic Factor
6%
Malignant Neoplasm
6%
Cisplatin
5%
Childhood Cancer
5%
Cancer
5%
Kidney Function
5%
Risk Stratification
5%
Pharmacology, Toxicology and Pharmaceutical Science
Rhabdomyosarcoma
44%
Chemotherapy
35%
Vincristine
32%
Cyclophosphamide
29%
Ifosfamide
23%
Neoplasm
17%
Etoposide
16%
Osteosarcoma
15%
Doxorubicin
14%
Dactinomycin
13%
Neutropenia
13%
Event Free Survival
12%
Pharmacokinetics
10%
Intrathecal
9%
Granulocyte Macrophage Colony Stimulating Factor
9%
Acute Myeloid Leukemia
9%
Diseases
8%
Idarubicin
7%
Cytarabine
7%
Methotrexate
7%
Amphotericin B
7%
Phase I Trials
7%
Recurrent Disease
7%
Amphotericin B Lipid Complex
6%
Ewing Sarcoma
6%
Antifungal Therapy
6%
Overall Survival
6%
Irinotecan
5%
Remission
5%
Lung Metastasis
5%
Failure Free Survival
5%
Malignant Neoplasm
5%